Esophageal Reflux Hypersensitivity: A Comprehensive Review

키워드

참고문헌 (113)

1. Aziz Q, "Functional esophageal disorders", Gastroenterology, 150, pp.P1368~P1379 (2016)
2. Galmiche JP, "Functional esophageal disorders", Gastroenterology, 130, pp.1459~1465 (2006)
3. Ashida K, "Randomised clinical trial : vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis", Aliment Pharmacol Ther, 43, pp.240~251 (2016)
4. Xiao Y, "Phase III, randomised, doubleblind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis", Gut, 69, pp.224~230 (2020)
5. Iwakiri K, "Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021", J Gastroenterol, 57, pp.267~285 (2022)
6. Cicala M, "Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease", World J Gastroenterol, 19, pp.6529~6535 (2013)
7. Okuyama M, "Factors associated with potassium-competitive acid blocker non-response in patients with proton pump inhibitor-refractory gastroesophageal reflux disease", Digestion, 95, pp.281~287 (2017)
8. Savarino E, "The role of nonacid reflux in NERD : lessons learned from impedance-pH monitoring in 150 patients off therapy", Am J Gastroenterol, 103, pp.2685~2693 (2008)
9. Kohata Y, "Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring", J Gastroenterol Hepatol, 27(Suppl 3), pp.58~62 (2012)
10. Weijenborg PW, "Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis", Am J Physiol Gastrointest Liver Physiol, 307, pp.G323~G329 (2014)
11. Eusebi LH, "Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms : a meta-analysis", Gut, 67, pp.430~440 (2018)
12. Martinez SD, "Nonerosive reflux disease(NERD) : acid reflux and symptom patterns", Aliment Pharmacol Ther, 17, pp.537~545 (2003)
13. Savarino E, "The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease", Dig Liver Dis, 43, pp.542~547 (2011)
14. Savarino E, "Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease", Gut, 58, pp.1185~1191 (2009)
15. Roman S, "Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux", Neurogastroenterol Motil, 27, pp.1667~1674 (2015)
16. Patel A, "Prevalence, characteristics, and treatment outcomes of reflux hypersensitivity detected on pH-impedance monitoring", Neurogastroenterol Motil, 28, pp.1382~1390 (2016)
17. Hemmink GJ, "Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms : ‘on’ or ‘off ’ proton pump inhibitor?", Am J Gastroenterol, 103, pp.2446~2453 (2008)
18. Sawada A, "Supragastric belching in Japan : lower prevalence and relevance for management of gastroesophageal reflux disease compared to United Kingdom", J Gastroenterol, 55, pp.1046~1053 (2020)
19. Tamura Y, "Pathophysiology of functional heartburn based on Rome III criteria in Japanese patients", World J Gastroenterol, 21, pp.5009~5016 (2015)
20. Fujiwara Y, "Epidemiology and clinical characteristics of GERD in the Japanese population", J Gastroenterol, 44, pp.518~534 (2009)
21. Yadlapati R, "Esophageal motility disorders on high-resolution manometry : Chicago classification version 4. 0©", Neurogastroenterol Motil, 33, pp.e14058~ (2021)
22. Pandolfino JE, "Achalasia : a systematic review", JAMA, 313, pp.1841~1852 (2015)
23. Wahba G, "Jackhammer esophagus : a meta-analysis of patient demographics, disease presentation, high-resolution manometry data, and treatment outcomes", Neurogastroenterol Motil, 32, pp.e13870~ (2020)
24. Hosaka H, "Clinical presentation and therapeutic outcome of patients with jackhammer esophagus : a multicenter cohort study in Japan", Esophagus, 19, pp.393~400 (2022)
25. Tutuian R, "Symptom and function heterogenicity among patients with distal esophageal spasm : studies using combined impedance-manometry", Am J Gastroenterol, 101, pp.464~469 (2006)
26. Yadlapati R, "AGA clinical practice update on the personalized approach to the evaluation and management of GERD : expert review", Clin Gastroenterol Hepatol, 20, pp.984~994 (2022)
27. Rengarajan A, "Overlap of functional heartburn and reflux hypersensitivity with proven gastroesophageal reflux disease", Neurogastroenterol Motil, 33, pp.e14056~ (2021)
28. Piche T, "Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome", Neurogastroenterol Motil, 22, pp.626~ (2010)
29. Gyawali CP, "Modern diagnosis of GERD : the Lyon Consensus", Gut, 67, pp.1351~1362 (2018)
30. Sifrim D, "Prolonged wireless pH monitoring or 24-hour catheter-based pH impedance monitoring : who, when, and why?", Am J Gastroenterol, 115, pp.1150~1152 (2020)
31. Hasak S, "Prolonged wireless pH monitoring in patients with persistent reflux symptoms despite proton pump inhibitor therapy", Clin Gastroenterol Hepatol, 18, pp.2912~2919 (2020)
32. Rogers BD, "Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease(GERD)patients with regurgitation", Gut, 70, pp.450~455 (2021)
33. Frazzoni L, "Application of Lyon Consensus criteria for GORD diagnosis : evaluation of conventional and new impedance-pH parameters", Gut, 71, pp.1062~1067 (2022)
34. Frazzoni M, "Esophageal chemical clearance is impaired in gastro-esophageal reflux disease : a 24-h impedance-pH monitoring assessment", Neurogastroenterol Motil, 25, pp.399~406 (2013)
35. Sifrim D, "Normal values and regional differences in oesophageal impedance-pH metrics : a consensus analysis of impedance-pH studies from around the world", Gut, 70, pp.1441~1449 (2021)
36. Trimble KC, "Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux : evidence for a spectrum of visceral sensitivity in GORD", Gut, 37, pp.7~12 (1995)
37. van Malenstein H, "Esophageal dilated intercellular spaces(DIS)and nonerosive reflux disease", Am J Gastroenterol, 103, pp.1021~1028 (2008)
38. Farré R, "Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique", Gut, 60, pp.885~892 (2011)
39. Woodland P, "In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease", Gut, 62, pp.1256~1261 (2013)
40. Weijenborg PW, "Esophageal acid sensitivity and mucosal integrity in patients with functional heartburn", Neurogastroenterol Motil, 28, pp.1649~1654 (2016)
41. Farré R, "Short exposure of oesophageal mucosa to bile acids, both in acidic and weakly acidic conditions, can impair mucosal integrity and provoke dilated intercellular spaces", Gut, 57, pp.1366~1374 (2008)
42. Caviglia R, "Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease patients with physiological esophageal acid exposure", Am J Gastroenterol, 100, pp.543~548 (2005)
43. Hopwood D, "Electron microscopic changes in human oesophageal epithelium in oesophagitis", J Pathol, 129, pp.161~167 (1979)
44. Zentilin P, "Reassessment of the diagnostic value of histology in patients with GERD, using multiple biopsy sites and an appropriate control group", Am J Gastroenterol, 100, pp.2299~2306 (2005)
45. Souza RF, "Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury", Gastroenterology, 137, pp.1776~1784 (2009)
46. Isomoto H, "Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease", Am J Gastroenterol, 99, pp.589~597 (2004)
47. Kondo T, "Prostaglandin E(2)mediates acid-induced heartburn in healthy volunteers", Am J Physiol Gastrointest Liver Physiol, 304, pp.G568~G573 (2013)
48. Kondo T, "A novel prostanoid EP1receptor antagonist, ONO-8539, reduces acid-induced heartburn symptoms in healthy male volunteers : a randomized clinical trial", J Gastroenterol, 52, pp.1081~1089 (2017)
49. Kondo T, "The nonsteroidal antiinflammatory drug diclofenac reduces acid-induced heartburn symptoms in healthy volunteers", Clin Gastroenterol Hepatol, 13, pp.1249~1255 (2015)
50. Sarkar S, "The prostaglandin E2receptor-1(EP-1)mediates acid-induced visceral pain hypersensitivity in humans", Gastroenterology, 124, pp.18~25 (2003)
51. Woodland P, "Distinct afferent innervation patterns within the human proximal and distal esophageal mucosa", Am J Physiol Gastrointest Liver Physiol, 308, pp.G525~G531 (2015)
52. Thoua NM, "Acidrelated oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease", Aliment Pharmacol Ther, 27, pp.396~403 (2008)
53. Bredenoord AJ, "Determinants of perception of heartburn and regurgitation", Gut, 55, pp.313~318 (2006)
54. Zerbib F, "Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors", Gut, 57, pp.156~160 (2008)
55. Woodland P, "Superficial esophageal mucosal afferent nerves may contribute to reflux hypersensitivity in nonerosive reflux disease", Gastroenterology, 153, pp.1230~1239 (2017)
56. Nikaki K, "Esophageal mucosal innervation in functional heartburn : closer to healthy asymptomatic subjects than to non-erosive reflux disease patients", Neurogastroenterol Motil, 31, pp.e13667~ (2019)
57. Gouin O, "TRPV1 and TRPA1 in cutaneous neurogenic and chronic inflammation : pro-inflammatory response induced by their activation and their sensitization", Protein Cell, 8, pp.644~661 (2017)
58. Blackshaw LA, "Transient receptor potential cation channels in visceral sensory pathways", Br J Pharmacol, 171, pp.2528~2536 (2014)
59. Matthews PJ, "Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus", Eur J Gastroenterol Hepatol, 16, pp.897~902 (2004)
60. Bhat YM, "Capsaicin receptor(TRPV1)and non-erosive reflux disease", Eur J Gastroenterol Hepatol, 18, pp.263~270 (2006)
61. Guarino MP, "Increased TRPV1 gene expression in esophageal mucosa of patients with nonerosive and erosive reflux disease", Neurogastroenterol Motil, 22, pp.746~751 (2010)
62. Ustaoglu A, "Heartburn sensation in nonerosive reflux disease : pattern of superficial sensory nerves expressing TRPV1 and epithelial cells expressing ASIC3 receptors", Am J Physiol Gastrointest Liver Physiol, 320, pp.G804~G815 (2021)
63. Krarup AL, "Randomized clinical trial : inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain", Scand J Gastroenterol, 48, pp.274~284 (2013)
64. Banovcin P, "The infusion of menthol into the esophagus evokes cold sensations in healthy subjects but induces heartburn in patients with gastroesophageal reflux disease(GERD)", Dis Esophagus, 32, pp.doz038~ (2019)
65. Chen CC, "Neurosensory mechanotransduction through acid-sensing ion channels", J Cell Mol Med, 17, pp.337~349 (2013)
66. Yoshida N, "Role of nociceptors", neuropeptides in the pathogenesis of visceral hypersensitivity of nonerosive reflux disease, 2013, pp.58, 2237~2243
67. Kandulski A, "Proteinaseactivated receptor-2 in the pathogenesis of gastroesophageal reflux disease", Am J Gastroenterol, 105, pp.1934~1943 (2010)
68. Yoshida N, "Interleukin-8 production via protease-activated receptor 2 in human esophageal epithelial cells", Int J Mol Med, 19, pp.335~340 (2007)
69. Wu L, "PAR-2 activation enhances weak acid-induced ATP release through TRPV1 and ASIC sensitization in human esophageal epithelial cells", Am J Physiol Gastrointest Liver Physiol, 309, pp.G695~G702 (2015)
70. Shaker R, "Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function : the results of a Gallup survey conducted on behalf of the American Gastroenterological Association", Am J Gastroenterol, 98, pp.1487~1493 (2003)
71. Kusano M, "Nationwide epidemiological study on gastroesophageal reflux disease and sleep disorders in the Japanese population", J Gastroenterol, 43, pp.833~841 (2008)
72. Fujiwara Y, "Gastroesophageal reflux disease and sleep disturbances", J Gastroenterol, 47, pp.760~769 (2012)
73. Schey R, "Sleep deprivation is hyperalgesic in patients with gastroesophageal reflux disease", Gastroenterology, 133, pp.1787~1795 (2007)
74. Yi CH, "Sleep disturbance and enhanced esophageal capsaicin sensitivity in patients with gastroesophageal reflux disease", J Gastroenterol Hepatol, 31, pp.1940~1945 (2016)
75. Farré R, "Critical role of stress in increased oesophageal mucosa permeability and dilated intercellular spaces", Gut, 56, pp.1191~1197 (2007)
76. Fujiwara Y, "Sleep dysfunction in Japanese patients with gastroesophageal reflux disease : prevalence, risk factors, and efficacy of rabeprazole", Digestion, 81, pp.135~141 (2010)
77. Losa M, "Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease", Neurogastroenterol Motil, 33, pp.e14177~ (2021)
78. Kessing BF, "Effects of anxiety and depression in patients with gastroesophageal reflux disease", Clin Gastroenterol Hepatol, 13, pp.1089~1095 (2015)
79. Taft TH, "Validation of the oesophageal hypervigilance and anxiety scale for chronic oesophageal disease", Aliment Pharmacol Ther, 47, pp.1270~1277 (2018)
80. Wong MW, "Oesophageal hypervigilance and visceral anxiety relate to reflux symptom severity and psychological distress but not to acid reflux parameters", Aliment Pharmacol Ther, 54, pp.923~930 (2021)
81. Guadagnoli L, "Esophageal hypervigilance is prevalent across gastroesophageal reflux disease presentations", Neurogastroenterol Motil, 33, pp.e14081~ (2021)
82. Taft TH, "Esophageal hypervigilance and symptom-specific anxiety in patients with eosinophilic esophagitis", Gastroenterology, 161, pp.1133~1144 (2021)
83. Carlson DA, "Esophageal hypervigilance and visceral anxiety are contributors to symptom severity among patients evaluated with high-resolution esophageal manometry", Am J Gastroenterol, 115, pp.367~375 (2020)
84. Kaji M, "Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life", J Gastroenterol Hepatol, 25, pp.1151~1156 (2010)
85. Vakil N, "Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population", United European Gastroenterol J, 4, pp.413~422 (2016)
86. Lovell RM, "Prevalence of gastro-esophageal refluxtype symptoms in individuals with irritable bowel syndrome in the community : a meta-analysis", Am J Gastroenterol, 107, pp.1793~1801 (2012)
87. de Bortoli N, "Functional heartburn overlaps with irritable bowel syndrome more often than GERD", Am J Gastroenterol, 111, pp.1711~1717 (2016)
88. Stanghellini V, "Gastroduodenal disorders", Gastroenterology, 150, pp.1380~1392 (2016)
89. Yadlapati R, "Postprandial high-resolution impedance manometry identifies mechanisms of nonresponse to proton pump inhibitors", Clin Gastroenterol Hepatol, 16, pp.211~218 (2018)
90. Sawada A, "Identification of different phenotypes of esophageal reflux hypersensitivity and implications for treatment", Clin Gastroenterol Hepatol, 19, pp.690~698 (2021)
91. Glasinovic E, "Treatment of supragastric belching with cognitive behavioral therapy improves quality of life and reduces acid gastroesophageal reflux", Am J Gastroenterol, 113, pp.539~547 (2018)
92. Takeda T, "Oesophageal wall stretch : the stimulus for distension induced oesophageal sensation", Neurogastroenterol Motil, 16, pp.721~728 (2004)
93. Tack J, "Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia", Gastroenterology, 121, pp.526~535 (2001)
94. Watson RG, "Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux : the"sensitive oesophagus"", Gut, 40, pp.587~590 (1997)
95. Taghavi SA, "Symptom association probability and symptom sensitivity index : preferable but still suboptimal predictors of response to high dose omeprazole", Gut, 54, pp.1067~1071 (2005)
96. Rodriguez-Stanley S, "A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn", Aliment Pharmacol Ther, 20, pp.975~982 (2004)
97. Marrero JM, "Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease", Gut, 35, pp.447~450 (1994)
98. Broeders JA, "Oesophageal acid hypersensitivity is not a contraindication to Nissen fundoplication", Br J Surg, 96, pp.1023~1030 (2009)
99. Rengarajan A, "Mean nocturnal baseline impedance correlates with symptom outcome when acid exposure time is inconclusive on esophageal reflux monitoring", Clin Gastroenterol Hepatol, 18, pp.589~595 (2020)
100. Spechler SJ, "Randomized trial of medical versus surgical treatment for refractory heartburn", N Engl J Med, 381, pp.1513~1523 (2019)
101. Desjardin M, "24-hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery : a single center retrospective study", Neurogastroenterol Motil, 28, pp.146~152 (2016)
102. Pauwels A, "How to select patients for antireflux surgery? The ICARUS guidelines (international consensus regarding preoperative examinations and clinical characteristics assessment to select adult patients for antireflux surgery)", Gut, 68, pp.1928~1941 (2019)
103. Limsrivilai J, "Imipramine for treatment of esophageal hypersensitivity and functional heartburn : a randomized placebo-controlled trial", Am J Gastroenterol, 111, pp.217~224 (2016)
104. Viazis N, "Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus : a randomized, double-blind, placebocontrolled study", Am J Gastroenterol, 107, pp.1662~1667 (2012)
105. Ostovaneh MR, "Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors : double-blind placebo-controlled trial", Neurogastroenterol Motil, 26, pp.670~678 (2014)
106. Blondeau K, "Baclofen improves symptoms and reduces postprandial flow events in patients with rumination and supragastric belching", Clin Gastroenterol Hepatol, 10, pp.379~384 (2012)
107. Kunte H, "Successful treatment of excessive supragastric belching by combination of pregabalin and baclofen", Psychiatry Clin Neurosci, 69, pp.124~125 (2015)
108. Hemmink GJ, "Speech therapy in patients with excessive supragastric belching : a pilot study", Neurogastroenterol Motil, 22, pp.24~28 (2010)
109. Murray HB, "Diagnosis and treatment of rumination syndrome : a critical review", Am J Gastroenterol, 114, pp.562~578 (2019)
110. Hoshikawa Y, "Rumination syndrome : assessment of vagal tone during and after meals and during diaphragmatic breathing", Neurogastroenterol Motil, 32, pp.e13873~ (2020)
111. Sawada A, "Management of supragastric belching with cognitive behavioural therapy : factors determining success and follow-up outcomes at 6-12 months post-therapy", Aliment Pharmacol Ther, 50, pp.530~537 (2019)
112. Robles A, "Outcomes of treating rumination syndrome with a tricyclic antidepressant and diaphragmatic breathing", Am J Med Sci, 360, pp.42~49 (2020)
113. Vakil N, "The Montreal definition and classification of gastroesophageal reflux disease : a global evidencebased consensus", Am J Gastroenterol, 101, pp.1900~1920 (2006)

관련 논문AI추천